{"log_id": 5756636906330870566, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.000211, "average": 0.975815, "min": 0.963978}, "location": {"width": 81, "top": 126, "height": 25, "left": 224}, "words": "母亲哺乳"}, {"probability": {"variance": 0, "average": 0.962373, "min": 0.962373}, "location": {"width": 23, "top": 140, "height": 25, "left": 1110}, "words": ":"}, {"probability": {"variance": 6.8e-05, "average": 0.984481, "min": 0.972276}, "location": {"width": 102, "top": 191, "height": 24, "left": 221}, "words": "[儿童用药]"}, {"probability": {"variance": 0.014948, "average": 0.955885, "min": 0.360172}, "location": {"width": 500, "top": 229, "height": 27, "left": 269}, "words": "16岁以下儿童患者使用本品的全性和有效性数据尚未建立"}, {"probability": {"variance": 0.049249, "average": 0.779029, "min": 0.463068}, "location": {"width": 133, "top": 296, "height": 25, "left": 215}, "words": "「老年患者用药"}, {"probability": {"variance": 0.036474, "average": 0.897725, "min": 0.406081}, "location": {"width": 719, "top": 332, "height": 28, "left": 261}, "words": "由于没有足的65岁及以上的老年患青参加本品的临床研尚不清楚老年患者与年"}, {"probability": {"variance": 0.020566, "average": 0.944344, "min": 0.368979}, "location": {"width": 767, "top": 371, "height": 28, "left": 213}, "words": "轻患者对本品的反应有何不同其他的临床试验报管发现老年患者与年轻患者之间的不"}, {"probability": {"variance": 0.005839, "average": 0.967094, "min": 0.591792}, "location": {"width": 760, "top": 408, "height": 29, "left": 212}, "words": "同、思替卡韦主要由肾脏排泄,在肾功能损伤的患者中,呼能发生毒性反应的危险性更高"}, {"probability": {"variance": 0.011875, "average": 0.963973, "min": 0.548894}, "location": {"width": 700, "top": 450, "height": 26, "left": 208}, "words": "因为老年患者多数育功能有所下降,因此应注意药物的选择并验测肾功能"}, {"probability": {"variance": 0.00792, "average": 0.960399, "min": 0.725386}, "location": {"width": 133, "top": 519, "height": 24, "left": 208}, "words": "[药物相互作用]"}, {"probability": {"variance": 0.010681, "average": 0.944317, "min": 0.512848}, "location": {"width": 710, "top": 554, "height": 27, "left": 251}, "words": "体内和体外试验评价了思替卡韦的代谢情况、思替卡韦不是细胞色素P450(CYP450"}, {"probability": {"variance": 0.01728, "average": 0.936438, "min": 0.422272}, "location": {"width": 763, "top": 591, "height": 31, "left": 204}, "words": "酶系统的底物、抑制剂或诱导剂,在浓度达到人体内浓度约10000倍时,恩替卡韦不抑制"}, {"probability": {"variance": 0.001133, "average": 0.974506, "min": 0.841784}, "location": {"width": 770, "top": 631, "height": 29, "left": 202}, "words": "何主要的人CYP450酶:1A2、2C9、2C19、2D6、3A4、2B6和2E1在浓度达到人体内浓度约"}, {"probability": {"variance": 0.008716, "average": 0.954493, "min": 0.541233}, "location": {"width": 767, "top": 667, "height": 30, "left": 202}, "words": "30倍时,思替卡韦不诱导人CYP450酶:1A2、2C9、2C19、3A4、3A5和2B6。同时服用通"}, {"probability": {"variance": 0.003945, "average": 0.971718, "min": 0.658289}, "location": {"width": 771, "top": 705, "height": 31, "left": 200}, "words": "过抑制或诱导CYP450系统而代谢的药物对恩替卡韦的药代动力学没有影响。而且,同时服"}, {"probability": {"variance": 0.000418, "average": 0.993673, "min": 0.894721}, "location": {"width": 469, "top": 747, "height": 26, "left": 199}, "words": "用恩替卡韦对已知的CYP底物的药代动力学也没有影响"}, {"probability": {"variance": 0.003824, "average": 0.979592, "min": 0.622931}, "location": {"width": 735, "top": 780, "height": 34, "left": 235}, "words": "研究思替卡韦与拉米夫定,阿福韦和特诺福韦的相互作用时,发现恩替卡韦和与其相"}, {"probability": {"variance": 0.002052, "average": 0.986386, "min": 0.800258}, "location": {"width": 349, "top": 822, "height": 32, "left": 196}, "words": "互作用药物的稳态药代动力学均没有改变"}, {"probability": {"variance": 0.010812, "average": 0.958862, "min": 0.599204}, "location": {"width": 729, "top": 858, "height": 32, "left": 240}, "words": "由于恩替卡韦主要通过肾脏清除,服用降低肾功能或竞争性通过生动肾小球分泌的药"}, {"probability": {"variance": 0.004601, "average": 0.975991, "min": 0.675518}, "location": {"width": 761, "top": 896, "height": 33, "left": 195}, "words": "物的同时,服用思替卡韦可能增加这两个药物的血药浓度。同时服用恩替卡韦与拉米夫定"}, {"probability": {"variance": 0.007662, "average": 0.964661, "min": 0.550377}, "location": {"width": 773, "top": 933, "height": 35, "left": 192}, "words": "阿德韦、特诺福韦不会引起明显的药物相互作用,同时服用恩替卡韦与其他通过肾脏清除"}, {"probability": {"variance": 0.007957, "average": 0.954615, "min": 0.620402}, "location": {"width": 772, "top": 973, "height": 33, "left": 192}, "words": "或已知影响肾功能的药物的相互作用尚米研究,患者在同时服用恩替卡韦与此类药物时要密"}, {"probability": {"variance": 0.025064, "average": 0.935145, "min": 0.462985}, "location": {"width": 185, "top": 1018, "height": 25, "left": 200}, "words": "刀监测不良反应的发生"}, {"probability": {"variance": 0.000303, "average": 0.980769, "min": 0.956414}, "location": {"width": 96, "top": 1083, "height": 26, "left": 193}, "words": "[药物过量]"}, {"probability": {"variance": 0.008657, "average": 0.964074, "min": 0.569509}, "location": {"width": 733, "top": 1113, "height": 36, "left": 229}, "words": "前尚无使用本品过量的相关报道。在健康人群中单次给药达40毫克或连续14天多"}, {"probability": {"variance": 0.012764, "average": 0.955775, "min": 0.478102}, "location": {"width": 773, "top": 1153, "height": 34, "left": 186}, "words": "次给药20mg/天后,未观察到不良事件发生的增多。如果发生药物过量,须监测患者的毒性"}, {"probability": {"variance": 0.000145, "average": 0.99221, "min": 0.954912}, "location": {"width": 274, "top": 1197, "height": 29, "left": 186}, "words": "指标,必要时进行标准支持疗法"}, {"probability": {"variance": 0.014787, "average": 0.94551, "min": 0.458272}, "location": {"width": 618, "top": 1230, "height": 35, "left": 228}, "words": "单次给药1mg恩替卡韦后,4个小时的血液透析可清除约13%的恩替卡韦"}, {"probability": {"variance": 9.9e-05, "average": 0.987455, "min": 0.975145}, "location": {"width": 49, "top": 1305, "height": 23, "left": 192}, "words": "规格]"}, {"probability": {"variance": 0.000268, "average": 0.989366, "min": 0.95726}, "location": {"width": 74, "top": 1342, "height": 22, "left": 184}, "words": "0.5毫克"}, {"probability": {"variance": 0.000266, "average": 0.972503, "min": 0.948874}, "location": {"width": 80, "top": 1402, "height": 24, "left": 181}, "words": "[有效期]"}], "language": 3}